Key takeaways
Skyrizi (risankizumab) and Cosentyx (secukinumab) are both injectable medications used to treat inflammatory conditions, but they have some key differences. Skyrizi is an interleukin-23 (IL-23) antagonist, while Cosentyx is an interleukin-17 (IL-17) inhibitor. Skyrizi is typically administered every 2 to 3 months after initial doses, whereas Cosentyx is usually given monthly after a series of weekly starter doses. Skyrizi is used for plaque psoriasis, psoriatic arthritis, and Crohn's disease, while Cosentyx treats plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, enthesitis-related arthritis, and hidradenitis suppurativa. Skyrizi is not approved for use in children, but Cosentyx can be used in children for certain conditions. Common side effects of Skyrizi include joint pain and upper respiratory infections, while Cosentyx may cause the common cold and diarrhea. Both medications can increase the risk of infections and should be used with caution if you have a history of infections.
